Biofluid biomarkers to track neurodegenerative diseases in vitam are urgently needed. Recent studies show that large-scale proteomic analyses based on the proximity extension assay may reveal novel biomarkers reflecting disease pathophysiology. Such biomarkers will likely express their maximal clinical value when used in combination with pathology-specific biomarkers.
Mastrangelo, A., Mammana, A., Parchi, P. (2023). Tracking neurodegenerative diseases in biofluids: Combining pathology and pathophysiology markers is the way. CELL CHEMICAL BIOLOGY, 30(11), 1340-1342 [10.1016/j.chembiol.2023.10.018].
Tracking neurodegenerative diseases in biofluids: Combining pathology and pathophysiology markers is the way
Mastrangelo, Andrea;Mammana, Angela;Parchi, Piero
2023
Abstract
Biofluid biomarkers to track neurodegenerative diseases in vitam are urgently needed. Recent studies show that large-scale proteomic analyses based on the proximity extension assay may reveal novel biomarkers reflecting disease pathophysiology. Such biomarkers will likely express their maximal clinical value when used in combination with pathology-specific biomarkers.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
